» Articles » PMID: 35318720

Incidence of Allopurinol-induced Severe Cutaneous Adverse Drug Reaction in Malaysia

Overview
Specialty Pharmacology
Date 2022 Mar 23
PMID 35318720
Authors
Affiliations
Soon will be listed here.
Abstract

Aims: Allopurinol is known to cause severe cutaneous adverse drug reactions (SCAR) in Malaysia. However, the incidence of allopurinol-induced SCAR is unknown. Therefore, we aimed to determine the incidence of allopurinol-induced SCAR in Malaysia over 5 years from 2015 to 2019.

Methods: This retrospective analysis was done in collaboration with the National Pharmaceutical Regulatory Agency (NPRA). All allopurinol-induced adverse drug reaction cases reported to NPRA from 2015 to 2019 were extracted. Allopurinol-induced SCAR cases were identified and the incidence over the 5 years was calculated.

Results: Incidence of allopurinol-induced SCAR averaged at 2.5 cases per 1000 new users over the 5-year period, with a reducing trend from 3.2 per 1000 new users in 2015 to 2.25 per 1000 in 2019; despite the increasing number of adverse drug reaction cases being reported over the years. Stevens-Johnson syndrome was the commonest form of allopurinol-induced SCAR reported, at 143 cases (46.8% of total SCAR reported). Among Malaysia's 3 main ethnicities, the Chinese had the highest percentages of allopurinol-induced SCAR when compared to the Bumiputera and Indians (3.18 × 10 %).

Conclusion: The estimated incidence of allopurinol-induced SCAR in Malaysia from 2015 to 2019 was 2.5 cases per 1000 new users. This figure is consistent with the incidence reported in other Asian countries, namely Taiwan and Thailand.

Citing Articles

Prevalence of HLA-B*58:01 allele among Malay, Chinese and Indian ethnic patients with gout attending primary care clinics in Malaysia.

Ng W, Kee B, Hussein N, Jenn Ng C, Kuan S, Mohd Zaidan F J Community Genet. 2024; .

PMID: 39586937 DOI: 10.1007/s12687-024-00753-4.


Effects of hydrogen-rich water on blood uric acid in patients with hyperuricemia: A randomized placebo-controlled trial.

Wu F, Ma J, Xue J, Jiang X, Liu J, Zhang J Heliyon. 2024; 10(16):e36401.

PMID: 39258191 PMC: 11385766. DOI: 10.1016/j.heliyon.2024.e36401.


Implementing HLA-B*58:01 testing prior to allopurinol initiation in Malaysian primary care setting: A qualitative study from doctors' and patients' perspective.

Ng W, Hussein N, Jenn Ng C, Qureshi N, Lee Y, Kwan Z PLoS One. 2024; 19(1):e0296498.

PMID: 38206925 PMC: 10783771. DOI: 10.1371/journal.pone.0296498.


Hepatic Safety of Febuxostat and Allopurinol for Gout Patients: A Systematic Review of Randomized Controlled Trial.

Dewi C, Puspita F, Puspitasari I, Zakiyah N Ther Clin Risk Manag. 2023; 19:731-743.

PMID: 37744559 PMC: 10516211. DOI: 10.2147/TCRM.S424598.


A Mobile App Leveraging Citizenship Engagement to Perform Anonymized Longitudinal Studies in the Context of COVID-19 Adverse Drug Reaction Monitoring: Development and Usability Study.

Di Filippo M, Avellone A, Belingheri M, Paladino M, Riva M, Zambon A JMIR Hum Factors. 2022; 9(4):e38701.

PMID: 35930561 PMC: 9640205. DOI: 10.2196/38701.